Background Non-vitamin K antagonist oral anticoagulants (NOACs) have been
recommended as preferred options for stroke prevention in patients with atrial fibrillation …

Background Non-vitamin K oral antagonist anticoagulants (NOACs) have been widely used
in stroke prevention in atrial fibrillation (SPAF). The aim of this study was to compare the …

What is known and objective With the high cost, the long‐term persistence of new oral
anticoagulants (NOACs) was lower than that of warfarin in Chinese patients with non …

We aimed to compare effectiveness and safety of the non‐vitamin K antagonist oral
anticoagulants (NOACs) vs. warfarin for stroke prevention in nonvalvular atrial fibrillation …

Objective The objective of this study was to assess the cost effectiveness of direct-acting oral
anticoagulants for stroke prevention in Thai patients with non-valvular atrial fibrillation and a …

The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) into clinical
practice represented a major change in the treatment of non-valvular atrial fibrillation …

Background and Purpose—There are limited real-world data comparing the effectiveness
and safety of non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in Asians …

BACKGROUND: The ARISTOTLE trial demonstrated that apixaban had significantly lower
rates of stroke/systemic embolism (SE) and major bleeding than warfarin; however, no direct …

Background Whether non–vitamin K antagonist oral anticoagulants (NOAC s) are superior to
warfarin among Asians with nonvalvular atrial fibrillation remains unclear. Methods and …

Purpose This study aimed to evaluate the cost-effectiveness of dabigatran and rivaroxaban
compared with warfarin for the prevention of stroke in patients with atrial fibrillation (AF) in …